Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3

Allos Therapeutics to Hold Q2 2004 Financial Results Conference
Call and Webcast on Tuesday, August 3 


WESTMINSTER, Colo., July 29  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) will hold a conference call Tuesday, August 3, 2004, at 4:30 PM
ET to discuss its second quarter 2004 financial results.

   Time:      4:30 PM ET
   Date:      Tuesday, August 3, 2004
   Dial-in:   [phone] / [phone] international
   Webcast:   http://www.allos.com/ (homepage and investor relations section)



Interested parties unable to participate in the live conference call may access
a recorded rebroadcast by dialing 888-203-1112, or [phone] for
international callers; the pass code number is 133938.  The replay will be
available from 7:30 p.m. ET on Tuesday, August 3, 2004 until 12:59 AM ET on
August 10, 2004.  In addition, the webcast will be archived for on-demand
listening for 30 days at http://www.allos.com/.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor
tissues and enhance the efficacy of standard radiation therapy.  In addition,
Allos is developing PDX, an injectable small molecule chemotherapeutic agent
that has a superior potency and toxicity profile relative to methotrexate and
other dihydrofolate reductase, or DHFR, inhibitors.  For more information,
please visit the company's web site at: http://www.allos.com/. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Media, Jennifer Neiman, Corporate Communications of Allos

Therapeutics, Inc., [phone], ; or Investors, Fern

Lazar of Lazar Partners Limited, [phone], ,

for Allos Therapeutics, Inc.



Web site:  http://www.allos.com/ 

Copyright